ENTITY
stringlengths 8
8
| DEFINITION
stringlengths 3
8.47k
⌀ | ALIASES
stringlengths 2
13.6k
⌀ | NAME
stringlengths 2
1.98k
|
|---|---|---|---|
C0700596 | A drug used to treat symptoms of advanced prostate cancer. It is also being studied in the treatment of other conditions and types of cancer. The active ingredient leuprolide blocks the body from making testosterone (a male hormone) and estradiol (a female hormone). It may stop the growth of prostate cancer cells that need testosterone to grow. Some brands of leuprolide are also used to treat early puberty in children and certain gynecologic conditions. Leuprolide acetate is a type of gonadotropin-releasing hormone analog. | Acetate, Leuprolide|Leuprorelin Acetate|leuprorelin acetate|Leuprolide acetate|D-leu6, desgly-NH2 10, proethylamide9-GnRH monoacetate|Leuprorelin acetate (substance)|6-D-Leucine-9-(N-ethyl-L-prolinamide)-1-9-luteinizing Hormone-releasing Factor (Pig) Monoacetate|LEUPROLIDE ACETATE|6-D-Leucine-9-(N-ethyl-L-prolinamide)-10-deglycinamide Luteinizing Hormone-Releasing Factor (Pig) Monoacetate|6-D-leucine-9-(N-ethyl-L-prolinamide)-10-deglycinamide luteinizing hormone-releasing factor (pig) monoacetate|D-Leu6, desGly-NH2 10-LHRH ethylamide monoacetate|Leuprorelin acetate|leuprolide acetate|6-D-leucine-9-(N-ethyl-L-prolinamide)-1-9-luteinizing hormone-releasing factor (pig) monoacetate|Leuprolide Acetate | leuprolide acetate |
C0008149 | Infections with bacteria of the genus CHLAMYDIA. | chlamydia infections|CHLAMYDIAL INFECTION|Chlamydial infection|Infection, Chlamydia|CHLAMYDIAL INFECTIONS|Infections, Chlamydia|chlamydial disease|Chlamydial Infection|Chlamydial infection NOS|Chlamydia Infection|Chlamydial infection (disorder)|Chlamydia infections|chlamydial infections|chlamydia bacteria infection|chlamydia infection|Chlamydia Infections|chlamydial infection | Chlamydia Infections |
C0033581 | Infiltration of inflammatory cells into the parenchyma of PROSTATE. The subtypes are classified by their varied laboratory analysis, clinical presentation and response to treatment. | Inflammation of prostate|Prostatitis NOS|prostate inflammation|Inflammatory diseases of prostate|PROSTATITIS|Prostatitis|Inflammation of the prostate|Prostatitis, unspecified|prostatitis|Prostatitis, NOS|Prostatitis (disorder)|Prostatitides | prostatitis |
C0002144 | A XANTHINE OXIDASE inhibitor that decreases URIC ACID production. It also acts as an antimetabolite on some simpler organisms. | 4-Hydroxy-1H-pyrazolo(3,4-d)pyrimidine|Allopurinol (substance)|4-Hydroxypyrazolopyrimidine|Allopurinolum|Product containing allopurinol (medicinal product)|ALLOPURINOL|allopurinol|4-Hydroxypyrazolo[3,4-d]pyrimidine|Allopurinol-containing product|1,5-Dihydro-4H-pyrazolo(3,4-d)pyrimidine-4-one|1,5-Dihydro-4H-pyrazolo(3,4-d)pyrimidin-4-one|Alopurinol|4-Hydroxypyrazolyl(3,4-d)pyrimidine|4H-Pyrazolo(3,4-d)pyrimidin-4-one, 1,5-dihydro-|4-Hydroxy-3,4-pyrazolopyrimidine|Allopurinol|4-hydroxypyrazolo[3,4-d]pyrimidine|1H-Pyrazolo(3,4-d)pyrimidin-4-ol|4H-Pyrazolo(3,4-d)pyrimidin-4-one|4-HPP|4'-Hydroxypyrazolol(3,4-d)pyrimidine|1H-Pyrazolo[3,4-d]pyrimidin-4-ol|1,5-Dihydro-4H-pyrazolo[3,4-d]pryimidin-4-one|4-Hydroxypyrazolo(3,4-d)pyrimidine|1,5-Dihydro-4H-pyrazolo[3,4-d]pyrimidin-4-one|4'-HPP | allopurinol |
C0017547 | The condition of accelerated and excessive GROWTH in children or adolescents who are exposed to excess HUMAN GROWTH HORMONE before the closure of EPIPHYSES. It is usually caused by somatotroph hyperplasia or a GROWTH HORMONE-SECRETING PITUITARY ADENOMA. These patients are of abnormally tall stature, more than 3 standard deviations above normal mean height for age. | Genetic giant|Giant, NOS|Gigantism (disorder)|Primordial giant|Gigantism, NOS|Giantism|genetics giant|gigantism|GIGANTISM, PITUITARY|Giant|Gigantism|Gigantosoma|GIGANTISM|giantism|giants|Giant, genetic|Giantism, NOS|gigantism disorder|Normal giant|Gigantism, Pituitary|giant|Pituitary Gigantism|Pituitary gigantism | Gigantism |
C1265953 | null | Focal hyperkeratosis (morphologic abnormality)|Focal keratosis | Focal hyperkeratosis |
C0442036 | relating to the sole of the foot | Plantar (qualifier value)|Plantar|plantar | Plantar - anatomical location |
C0591427 | null | Dysport|dysport | Dysport |
C0317763 | A rapid-growing, nonphotochromogenic species that is potentially pathogenic, producing lesions of lung, bone, or soft tissue following trauma. It has been found in soil and in injection sites of humans, cattle, and cold-blooded animals. (Dorland, 28th ed) | Mycobacterium minetti|Mycobacterium fortuitum (organism)|mycobacterium fortuitum|Mycolicibacterium fortuitum|Mycobacterium giae|fortuitum mycobacterium|Mycobacterium ranae|Mycobacterium fortuitum|MYCOBACTERIUM FORTUITUM | Mycobacterium fortuitum |
C0333747 | null | Molluscum bodies (morphologic abnormality)|Molluscum bodies | Molluscum bodies |
C0014742 | A skin and mucous membrane disease characterized by an eruption of macules, papules, nodules, vesicles, and/or bullae with characteristic "bull's-eye" lesions usually occurring on the dorsal aspect of the hands and forearms. | Erythema multiforme|Target lesion|Erythema multiforme, unspecified|erythema multiforme|Erythema multiforme, NOS|EM - Erythema multiforme|ERYTHEMA MULTIFORME|erythema polymorphe|erythema multiformes|Erythema multiforme (disorder)|multiforme erythema|Erythema Multiforme | Erythema Multiforme |
C0497406 | Being too heavy for one's height. Excess body weight can come from fat, muscle, bone, and/or water retention. Being overweight does not always mean being obese. | Overweight|overweight|OVERWEIGHT|clinical overweight|OVER WEIGHT|Overweight (finding)|Patient overweight | Overweight |
C0038492 | Individuals enrolled in a school or formal educational program. | Student|Student (occupation)|Student, NOS|Students|RoleClassStudent|students|student | student |
C0086931 | null | risk behaviors|Behavior, Risk|behavior risk|Behaviors, Risk|risk behavior|Risk Behaviors | Risk Behavior |
C0036375 | Educational institutions. | educational institution|environment school|Educational Institution|SCHOOL|School|educational organization|schools|school|School (environment)|Schools | School |
C0024028 | Affection; in psychiatry commonly refers to pleasure, particularly as it applies to gratifying experiences between individuals. | loving|loved|love|Loves|loves|Love (finding)|Love | Love |
C0005823 | PRESSURE of the BLOOD on the ARTERIES and other BLOOD VESSELS. | blood pressure|Blood Pressure|Blood pressure (observable entity)|Pressure, Blood|BP - Blood pressure|BP|Blood pressure|BLOOD PRESSURE|Blood pressure, NOS | Blood Pressure |
C0497247 | A finding of increased blood pressure; not necessarily hypertensive disorder | Elevated Blood Pressure|Elevated blood pressure|rise in blood pressure|blood increase pressure|Finding of increased blood pressure|Increased blood pressure|elevate blood pressure|blood pressure rises|increase blood pressure|PRESSURE BLOOD INCREASED|elevated bp|Finding of increased blood pressure (finding)|blood elevates pressure|blood elevate pressure|blood pressure rise|Raised blood pressure|increased blood pressure|Blood pressure elevation|blood increasing pressure|blood pressure raising|blood pressure elevated|increase in blood pressure|blood pressure elevation|blood pressure increase|ARTERIAL PRESSURE HIGH|elevated blood pressure|BLOOD PRESSURE ELEVATED|BLOOD PRESSURE INCREASED|elevation blood pressure|blood elevation pressure|blood increases pressure|Increased BP|blood elevations pressure | Increase in blood pressure |
C0281192 | null | prevention of skin cancer|Skin Cancer Prevention|skin cancer prevention|cancer prevention skin|prevention skin cancer | Prevention of Skin Cancer |
C0027586 | A species of intestinal nematode parasites which occur most commonly in mice. Infection is by ingesting larvae. This particular species is used extensively in immunological research. | Nematospiroides dubius|Heligmosomoides polygyrus | Nematospiroides dubius |
C0025929 | mouse that has been bred or acquired for the purpose of being a research subject in a facility where scientific research and experiments are conducted. | Laboratory Mouse|Mice, Laboratory|Laboratory Mice|Mouse, laboratory|mouse|Mouse, Laboratory|laboratory mice|Laboratory mouse|mice|laboratory mouse|Laboratory mouse (organism) | Laboratory mice |
C0025605 | A synthetic opioid that is used as the hydrochloride. It is an opioid analgesic that is primarily a mu-opioid agonist. It has actions and uses similar to those of MORPHINE. (From Martindale, The Extra Pharmacopoeia, 30th ed, p1082-3) | METHADONE|(±)-methadone|methadone|Methadonum|dl-Methadone|3-Heptanone, 6-(dimethylamino)-4,4-diphenyl-|Metadona|Methadone|Product containing methadone (medicinal product)|Methadone (substance)|6-Dimethylamino-4,4-diphenyl-3-heptanone|Methadone-containing product|(+-)-Methadone|(+/-)-Methadone | methadone |
C0006405 | A derivative of the opioid alkaloid THEBAINE that is a more potent and longer lasting analgesic than MORPHINE. It appears to act as a partial agonist at mu and kappa opioid receptors and as an antagonist at delta receptors. The lack of delta-agonist activity has been suggested to account for the observation that buprenorphine tolerance may not develop with chronic use. | 6,14-Ethenomorphinan-7-methanol, 17-(cyclopropylmethyl)-alpha-(1,1-dimethylethyl)-4,5-epoxy-18,19-dihydro-3-hydroxy-6-methoxy-alpha-methyl-, (5alpha,7alpha(S))-|Buprenophine|Product containing buprenorphine (medicinal product)|Buprenorphine|Buprenorphine-containing product|buprenorphine|21-cyclopropyl-7α-[(S)-1-hydroxy-1,2,2-trimethylpropyl]-6,14-endo-ethano-6,7,8,14-tetrahydrooripavine|2-[3-cyclopropylmethyl-11-hydroxy-15-methoxy-(14R)-13-oxa-3-azahexacyclo[13.2.2.12,8.01,6.06,14.07,12]icosa-7,9,11-trien-16-yl]-3,3-dimethyl-2-butanol|Buprenorphinum|Buprenorphine (substance)|17-cyclopropylmethyl-4,5α-epoxy-7α-((S)-1-hydroxy-1,2,2-trimethylpropyl)-6-methoxy-6,14-endo-ethanomorphinan-3-ol|BUPRENORPHINE|2-(N-cyclopropylmethyl-4,5α-epoxy-3-hydroxy-6-methoxy-6,14-endo-ethanomorphinan-6α-yl)-3,3-dimethyl-2-butanol|Buprenorfina|(-)-buprenorphine | buprenorphine |
C0324306 | The Beagle is a hardy, sturdy squarely-built, small hound, with a short coat in tri-color, red and white, orange and white, or lemon and white. The ears are long, wide and pendant. There are two height classes, 13-15 inches (33-38 cm.) and under 13 inches (33 cm.) Weight: 20-25 pounds (9-11 kg.) | Beagle|Beagle (organism)|beagles|beagle|BEAGLE | Beagle |
C0684085 | null | null | cutaneous membrane |
C0066412 | null | Product containing methyl nicotinate (medicinal product)|Methyl nicotinate (substance)|Nicotinic acid, methyl ester|Methyl 3-pyridinecarboxylate|Methyl Nicotinate|Methyl nicotinate|3-pyridinecarboxylic acid methyl ester|3-(Methoxycarbonyl)pyridine|3-(Carbomethoxy)pyridine|Methyl nicotinate-containing product|METHYL NICOTINATE|Methylnicotinate|Methyl-nicotinate|methylnicotinate|methyl nicotinate | methylnicotinate |
C0043474 | A dideoxynucleoside compound in which the 3'-hydroxy group on the sugar moiety has been replaced by an azido group. This modification prevents the formation of phosphodiester linkages which are needed for the completion of nucleic acid chains. The compound is a potent inhibitor of HIV replication, acting as a chain-terminator of viral DNA during reverse transcription. It improves immunologic function, partially reverses the HIV-induced neurological dysfunction, and improves certain other clinical abnormalities associated with AIDS. Its principal toxic effect is dose-dependent suppression of bone marrow, resulting in anemia and leukopenia. | Compound S|1-(3-Azido-2,3-dideoxy-beta-D-ribofuranosyl)-5-methylpyrimidine-2,4-(1H,3H)-dione|compound s|azt|zdv|AZT Antiviral|Azidothymidine|ZDV|Product containing zidovudine (medicinal product)|zidovudine (AZT)|zidovudine|Zidovudinum|Antiviral AZT|Zidovudina|Zidovudine (substance)|3' Azido 3' deoxythymidine|3' Azido 2',3' Dideoxythymidine|3'-Azido-3'-deoxythymidine|AZT, Antiviral|AZT (Antiviral)|AZT|azidodeoxythymidine|Zidovudine|3'-Azido-2',3'-Dideoxythymidine|azidothymidine|ZIDOVUDINE|Thymidine, 3'-azido-3'-deoxy-|3'-azido-3'-deoxythymidine|Zidovudine-containing product|s compound | zidovudine |
C0278080 | A condition in which a person takes a drug over time, and unpleasant physical symptoms occur if the drug is suddenly stopped or taken in smaller doses. | Physical Dependence|Physiological addiction|physical addiction|physiological Alcohol or Other Drugs dependence|physiological AOD dependence|biological Alcohol or Other Drugs dependence|physical dependence|Physical addiction (finding)|Addiction, physical|DEPENDENCE PHYSIOLOGICAL|biological alcohol or other drug dependence|physical Alcohol or Other Drugs dependence|physical AOD dependence|physiological dependence|physiological addiction|Physical addiction|biological AOD dependence | Physical addiction |
C0006405 | A derivative of the opioid alkaloid THEBAINE that is a more potent and longer lasting analgesic than MORPHINE. It appears to act as a partial agonist at mu and kappa opioid receptors and as an antagonist at delta receptors. The lack of delta-agonist activity has been suggested to account for the observation that buprenorphine tolerance may not develop with chronic use. | 6,14-Ethenomorphinan-7-methanol, 17-(cyclopropylmethyl)-alpha-(1,1-dimethylethyl)-4,5-epoxy-18,19-dihydro-3-hydroxy-6-methoxy-alpha-methyl-, (5alpha,7alpha(S))-|Buprenophine|Product containing buprenorphine (medicinal product)|Buprenorphine|Buprenorphine-containing product|buprenorphine|21-cyclopropyl-7α-[(S)-1-hydroxy-1,2,2-trimethylpropyl]-6,14-endo-ethano-6,7,8,14-tetrahydrooripavine|2-[3-cyclopropylmethyl-11-hydroxy-15-methoxy-(14R)-13-oxa-3-azahexacyclo[13.2.2.12,8.01,6.06,14.07,12]icosa-7,9,11-trien-16-yl]-3,3-dimethyl-2-butanol|Buprenorphinum|Buprenorphine (substance)|17-cyclopropylmethyl-4,5α-epoxy-7α-((S)-1-hydroxy-1,2,2-trimethylpropyl)-6-methoxy-6,14-endo-ethanomorphinan-3-ol|BUPRENORPHINE|2-(N-cyclopropylmethyl-4,5α-epoxy-3-hydroxy-6-methoxy-6,14-endo-ethanomorphinan-6α-yl)-3,3-dimethyl-2-butanol|Buprenorfina|(-)-buprenorphine | buprenorphine |
C0538927 | A pyrazole derivative and selective CYCLOOXYGENASE 2 INHIBITOR that is used to treat symptoms associated with RHEUMATOID ARTHRITIS; OSTEOARTHRITIS and JUVENILE ARTHRITIS, as well as the management of ACUTE PAIN. | celecoxib|Celecoxib-containing product|CELECOXIB|Celecoxib (substance)|Benzenesulfonamide, 4-[5-(4-methylphenyl)-3-(trifluoromethyl)-1H-pyrazol-1-yl]-|p-(5-p-Tolyl-3-(trifluoromethyl)pyrazol-1-yl)benzenesulfonamide|Célécoxib|4-(5-(4-methylphenyl)-3-(trifluoromethyl)-1H-pyrazol-1-yl)benzenesulfonamide|Product containing celecoxib (medicinal product)|Celecoxibum|Celecoxib | celecoxib |
C1257954 | A nonsteroidal anti-inflammatory drug used to relieve pain and inflammation. COX-2 inhibitors are being studied in the prevention of colon polyps, and as anticancer drugs. | Cyclooxygenase 2 Inhibitors|cox 2 inhibitors|coxib|PTGS-2 inhibitor|Cyclooxygenase-2 inhibitor-containing product|Substance with prostaglandin-endoperoxide synthase isoform 2 inhibitor mechanism of action (substance)|Inhibitors, COX2|COX 2 Inhibitors|COX2 Inhibitors|PTGS2 Inhibitor|Product containing prostaglandin-endoperoxide synthase isoform 2 inhibitor (product)|Cyclooxygenase-2 Inhibitors|coxibs|Inhibitors, COX-2|Cyclooxygenase-2 inhibitor|COX-2 Inhibitors|Prostaglandin-endoperoxide synthase isoform 2 inhibitor|cox 2 inhibitor|Inhibitors, Cyclooxygenase-2|COX-2 inhibitor-containing product|PTGS-2 inhibitor-containing product|Prostaglandin-endoperoxide synthase isoform 2 inhibitor-containing product|COX-2 inhibitor|Prostaglandin-Endoperoxide Synthase 2 Inhibitor|Coxibs|cox-2 inhibitor|cyclooxygenase-2 inhibitors|COX2 inhibitor|Cyclooxygenase II Inhibitor|Inhibitors, Cyclooxygenase 2|cyclooxygenase-2 inhibitor|COX-2 Inhibitor | Cyclooxygenase 2 Inhibitors |
C1150132 | OBSOLETE. Catalysis of the cleavage at the terminal bond of the motif: Asp-Xaa-Xaa-Asp-Xaa. Enzymes with this function are members of the peptidase family C14 and they appear to function in the inactivation of proteins involved in cellular repair and homeostasis during the effector stage of apoptosis. [ISBN:0120793709] | null | caspase-3 activity |
C0257343 | A drug used to treat urinary problems caused by an enlarged prostate. Tamsulosin relaxes the muscles of the prostate and bladder, which helps the flow of urine. It is a type of alpha blocker. | Tamsulosinum|5-(2-((2-(2-Ethoxyphenoxy)ethyl)amino)propyl)-2-methoxybenzenesulfonamide|Tamsulosin|(R)-(-)-tamsulosin|Tamsulosin (substance)|Product containing tamsulosin (medicinal product)|TAMSULOSIN|Tamsulosina|Tamsulosine|Tamsulosin-containing product|5-((2R)-2-(2-(2-ethoxyphenoxy)ethylamino)propyl)-2-methoxy-benzenesulfonamide|tamsulosin|(-)-tamsulosin|(R)-5-(2-((2-(2-ethoxyphenoxy)ethyl)amino)propyl)-2-methoxybenzenesulfonamide | tamsulosin |
C0032912 | A selective adrenergic alpha-1 antagonist used in the treatment of HEART FAILURE; HYPERTENSION; PHEOCHROMOCYTOMA; RAYNAUD DISEASE; PROSTATIC HYPERTROPHY; and URINARY RETENTION. | 2-[4-(2-furoyl)piperazin-1-yl]-4-amino-6,7-dimethoxyquinazoline|Prazosin (substance)|prazosin|Prazosin-containing product|Prazosina|Prazosine|Piperazine, 1-(4-amino-6,7-dimethoxy-2-quinazolinyl)-4-(2-furanylcarbonyl)-|Prazosinum|Product containing prazosin (medicinal product)|Prazosin|2-(4-(2-Furoyl)piperazin-1-yl)-4-amino-6,7-dimethoxyquinazoline|1-(4-Amino-6,7-dimethoxy-2-quinazolinyl)-4-(2-furanylcarbonyl)piperazine|Furazosin|PRAZOSIN|1-(4-amino-6,7-dimethoxy-2-quinazolinyl)-4-(2-furanylcarbonyl)piperazine | prazosin |
C0077857 | null | URAPIDIL|6-(3-(4-(o-methoxyphenyl)-1-piperazinyl)propylamino)-1,3-dimethyluracil|6-((3-(4- (2-methoxyphenyl)-1-piperazinyl)propyl)amino)- 1,3-dimethyl-2,4(1H,3H)-pyrimidinedione|urapidil|Urapidil (substance)|Urapidil | urapidil |
C0257343 | A drug used to treat urinary problems caused by an enlarged prostate. Tamsulosin relaxes the muscles of the prostate and bladder, which helps the flow of urine. It is a type of alpha blocker. | Tamsulosinum|5-(2-((2-(2-Ethoxyphenoxy)ethyl)amino)propyl)-2-methoxybenzenesulfonamide|Tamsulosin|(R)-(-)-tamsulosin|Tamsulosin (substance)|Product containing tamsulosin (medicinal product)|TAMSULOSIN|Tamsulosina|Tamsulosine|Tamsulosin-containing product|5-((2R)-2-(2-(2-ethoxyphenoxy)ethylamino)propyl)-2-methoxy-benzenesulfonamide|tamsulosin|(-)-tamsulosin|(R)-5-(2-((2-(2-ethoxyphenoxy)ethyl)amino)propyl)-2-methoxybenzenesulfonamide | tamsulosin |
C0083381 | An oxicam derivative and a non-steroidal anti-inflammatory drug (NSAID) with anti-inflammatory, antipyretic and analgesic activities. Unlike traditional nonselective NSAIDs, meloxicam preferentially inhibits the activity of cyclo-oxygenase II (COX-II), resulting in a decreased conversion of arachidonic acid into prostaglandin precursors. The resulting decrease in prostaglandin synthesis is responsible for the therapeutic effects of meloxicam. | Miloxicam|miloxicam|4-Hydroxy-2-methyl-N-(5-methyl-2-thiazolyl)-2H-1,2-benzothiazine-3-carboxamide 1,1-dioxide|Meloxicam|Meloxicam (substance)|Méloxicam|Meloxicam-containing product|Meloxicamum|meloxicam|2H-1,2-Benzothiazine-3-carboximidic acid, 4-hydroxy-2-methyl-N-(5-methyl-2-thiazolyl)-, 1,1-dioxide|Product containing meloxicam (medicinal product)|MELOXICAM | meloxicam |
C0145988 | A family of secreted protease inhibitory proteins that regulates the activity of SECRETED MATRIX METALLOENDOPEPTIDASES. They play an important role in modulating the proteolysis of EXTRACELLULAR MATRIX, most notably during tissue remodeling and inflammatory processes. | tissue inhibitor of metalloproteinase (TIM)|Metalloproteinases Tissue Inhibitor|Tissue Inhibitor of Metalloproteinases|tissue inhibitor of metalloproteinase|TIMP|timp|Proteins, TIMP|TIMP Proteins | Tissue Inhibitor of Metalloproteinases |
C0623362 | A family of zinc-dependent metalloendopeptidases that is involved in the degradation of EXTRACELLULAR MATRIX components. | Metalloproteinases, Matrix|mmps|Matrix Metalloproteinases|Matrix Metalloprotease|MMP|Matrix Metalloproteinase|matrix metalloproteinase|matrix metalloproteinases|MMPs | Matrix Metalloproteinases |
C1280344 | null | Entire vas deferens (body structure)|Entire vas deferens | Entire vas deferens |
C0008845 | A furancarbonitrile that is one of the serotonin uptake inhibitors used as an antidepressant. The drug is also effective in reducing ethanol uptake in alcoholics and is used in depressed patients who also suffer from TARDIVE DYSKINESIA in preference to tricyclic antidepressants, which aggravate dyskinesia. | Citalopramum|Citalopram (substance)|CITALOPRAM|5-Isobenzofurancarbonitrile, 1-(3-(dimethylamino)propyl)-1-(4-fluorophenyl)-1,3-dihydro-|Citalopram|Citalopram-containing product|Product containing citalopram (medicinal product)|cytalopram|1,3-Dihydro-1-(3-(dimethylamino)propyl)-1-(4-fluorophenyl)-5-isobenzofurancarbonitrile|Cytalopram|citalopram | citalopram |
C0525227 | An imidazole derivative and a selective alpha-2 adrenergic receptor agonist. Upon ocular administration, brimonidine acts on the blood vessels causing them to constrict which leads to a decrease in the production of aqueous humor. Brimonidine also enhances the uveoscleral outflow of aqueous humor. This reduces intraocular pressure. | 5-bromo-6-(imidazolidinylideneamino)quinoxaline|Brimonidina|5-Bromo-6-(2-imidazolin-2-ylamino)quinoxaline|5-bromo-6-(imidazolin-2-ylamino)quinoxaline|Brimonidine-containing product|Brimonidinum|Brimonidine (substance)|Brimonidine|Brimodine|BRIMONIDINE|brimonidine|Product containing brimonidine (medicinal product)|Bromoxidine | brimonidine |
C0019392 | A flavanone glycoside found in CITRUS fruit peels. | hesperidin|Ciratin|Hesperidina|Hesperetin 7 Rutinoside|Hesperidin 2S|(S)-(-)-hesperidin|4H-1-Benzopyran-4-one, 7-((6-O-(6-deoxy-alpha-L-mannopyranosyl)-beta-D-glucopyranosyl)oxy)-2,3-dihydro-5-hydroxy-2-(3-hydroxy-4-methoxyphenyl)-, (S)-|HESPERIDIN|Hesperetin 7-O-rutinoside|2S, Hesperidin|Hesperetin-7-Rutinoside|Hesperidin|7-Rhamnoglucoside, Hesperetin|Hesperetin 7-Rhamnoglucoside|Hesperidoside|Cirantin|Hesperetin Glycoside|Hesperidin (substance)|Hesperetin 7 Rhamnoglucoside | hesperidin |
C0062585 | A flavanone with hydroxyl groups at C-5, C-7, and C-5' and a methoxyl group at C-4'. | Eriodictyol 4'-monomethyl Ether|4h-1-benzopyran-4-one, 2,3-dihydro-5,7-dihydroxy-2-(3-hydroxy-4-methoxyphenyl)-, (S)-|hesperetin|4h-1-benzopyran-4-one, 2,3-dihydro-5,7-dihydroxy-2-(3-hydroxy-4-methoxyphenyl)-, (2S)-|HESPERETIN|2,3-dihydro-5,7-dihydroxy-2-(3-hydroxy-4-methoxyphenyl)-4h-1-benzopyran-4-one|hesperitin|(-)-Hesperetin|Hesperetin|Flavanone, 3',5,7-trihydroxy-4'-methoxy-|5,7,3'-trihydroxy-4'-methoxyflavanone|Hesperitin|3',5,7-trihydroxy-4'-methoxyflavanone | hesperetin |
C0019392 | A flavanone glycoside found in CITRUS fruit peels. | hesperidin|Ciratin|Hesperidina|Hesperetin 7 Rutinoside|Hesperidin 2S|(S)-(-)-hesperidin|4H-1-Benzopyran-4-one, 7-((6-O-(6-deoxy-alpha-L-mannopyranosyl)-beta-D-glucopyranosyl)oxy)-2,3-dihydro-5-hydroxy-2-(3-hydroxy-4-methoxyphenyl)-, (S)-|HESPERIDIN|Hesperetin 7-O-rutinoside|2S, Hesperidin|Hesperetin-7-Rutinoside|Hesperidin|7-Rhamnoglucoside, Hesperetin|Hesperetin 7-Rhamnoglucoside|Hesperidoside|Cirantin|Hesperetin Glycoside|Hesperidin (substance)|Hesperetin 7 Rhamnoglucoside | hesperidin |
C0068450 | A flavanone with hydroxyl groups at C-5, C-7, and C-4'. | 5,7,4'-Trihydroxyflavanone|NARINGENIN|naringenin|Naringenin|Salipurol|(S)-Naringenin|(S)-2,3-Dihydro-5,7-dihydroxy-2-(4-hydroxyphenyl)-4H-1-benzopyran-4-one|Naringetol|Salipurpol|4',5,7-trihydroxyflavanone | naringenin |
C1570123 | null | null | Vimang |
C1570123 | null | null | Vimang |
C1570123 | null | null | Vimang |
C0340865 | null | Anaphylactoid reaction|Anaphylactoid Shock|anaphylactoid reaction|Reaction, Anaphylactoid|Anaphylactoid Reaction|Anaphylactoid Shocks|Anaphylactoid reaction NOS|Anaphylactoid reaction (disorder)|ANAPHYLACTOID REACTION|Anaphylactoid Reactions|REACTION ANAPHYLACTIC ANAPHYLACTOID|SHOCK ANAPHYLACTIC ANAPHYLACTOID|Shock, Anaphylactoid|Anaphylactoid shock|anaphylactoid reactions|anaphylactoid shock | Anaphylactoid Reaction |
C0065654 | null | MANGIFERIN|mangiferin|2-beta-D-glucopyranosyl-1,3,6,7-tetrahydroxy-9H-xanthen-9-one|9H-xanthen-9-one, 2-beta-D-glucopyranosyl-1,3,6,7-tetrahydroxy-|chinonin|alpizarin | mangiferin |
C0033405 | A phenothiazine derivative with histamine H1-blocking, antimuscarinic, and sedative properties. It is used as an antiallergic, in pruritus, for motion sickness and sedation, and also in animals. | PROMETHAZINE|Promethazinum|Promethazine (substance)|Promethazine-containing product|Prometazina|10-(2-Dimethylaminopropyl)phenothiazine|N,N,α-trimethyl-10H-phenothiazine-10-ethanamine|(2-dimethylamino-2-methyl)ethyl-N-dibenzoparathiazine|10H-Phenothiazine-10-ethanamine, N,N,alpha-trimethyl-|promethazine|N,N,alpha-trimethyl-10H-phenothiazine-10-ethanamine|prometazin|10-[2-(dimethylamino)propyl]phenothiazine|Product containing promethazine (medicinal product)|Prometazin|N-(2'-dimethylamino-2'-methyl)ethylphenothiazine|Proazamine|Promethazine | promethazine |
C0030015 | Binary compounds of oxygen containing the anion O(2-). The anion combines with metals to form alkaline oxides and non-metals to form acidic oxides. | oxides|oxide|Oxides|Oxides (substance) | Oxides |
C0040778 | A propylamine formed from the cyclization of the side chain of amphetamine. This monoamine oxidase inhibitor is effective in the treatment of major depression, dysthymic disorder, and atypical depression. It also is useful in panic and phobic disorders. (From AMA Drug Evaluations Annual, 1994, p311) | trans-2-Phenylcyclopropylamine|Racemic Tranylcypromine|dl-tranylcypromine|Product containing tranylcypromine (medicinal product)|Tranylcypromin|Tranylcypromine (substance)|(1R*,2S*)-2-phenylcyclopropan-1-amine|trans-2-phenylcyclopropylamine|Tranylcyprominum|trans-DL-2-Phenylcyclopropylamine|Cyclopropanamine, 2-phenyl-, trans-(+-)-|Tranylcypromine-containing product|(±)-trans-2-phenylcyclopropylamine|Tranilcipromina|Tranylcypromine|trans 2 Phenylcyclopropylamine|TRANYLCYPROMINE|tranylcypromine | tranylcypromine |
C0022635 | An IBUPROFEN-type anti-inflammatory analgesic and antipyretic. It is used in the treatment of rheumatoid arthritis and osteoarthritis. | Capisten|benzeneacetic Acid, 3-benzoyl-alpha-methyl-|m-Benzoylhydratropic acid|ketoprofen|propionic scid, 2-(3-benzoylphenyl)-|capisten|3-Benzoyl-alpha-methylbenzeneacetic acid|Benzeneacetic acid, 3-benzoyl-alpha-methyl-|3-Benzoylhydratropic acid|L'acide (benzoyl-3-phenyl)-2-propionique|Ketoprofen|Product containing ketoprofen (medicinal product)|Propionic Acid, 2-(3-benzoylphenyl)-|Ketoprofen-containing product|Ketoprofen (substance)|KETOPROFEN|Ketoprofeno|Benzeneacetic Acid, 3-benzoyl-alpha-methyl-|2-(3-Benzoylphenyl)propionic Acid|2-(3-Benzoylphenyl)propionic acid|3-Benzoyl-α-methylbenzeneacetic acid|Benzoylhydratropic Acid | ketoprofen |
C0028127 | A calcium channel blocker with marked vasodilator action. It is an effective antihypertensive agent and differs from other calcium channel blockers in that it does not reduce glomerular filtration rate and is mildly natriuretic, rather than sodium retentive. | Nitrendipino|NITRENDIPINE|nitrendipine|3,5-Pyridinedicarboxylic acid, 1,4-dihydro-2,6-dimethyl-4-(3-nitrophenyl)-, ethyl methyl ester|1,4-dihydro-2,6-dimethyl-4-(3-nitrophenyl)-3,5-pyridinedicarboxylic acid ethyl methyl ester|Nitrendipine|Nitrendipinum|Nitrendipine (substance) | nitrendipine |
C0014822 | Glycoprotein hormone, secreted chiefly by the KIDNEY in the adult and the LIVER in the FETUS, that acts on erythroid stem cells of the BONE MARROW to stimulate proliferation and differentiation. | epos|EPO - Erythropoietin|hematopoietin|Erythropoietin|Erythropoietin preparation|erythropoietin|Epo|Product containing erythropoietin (medicinal product)|erythropoietins|Erythropoietin (substance)|E.P.O.|ECSF|Erythropoietin-containing product|erythrocyte colony stimulating factor|ECSF (erythrocyte colony stimulating factor)|Erythropoetin|epo | Erythropoietin |
C0014802 | The cells in the erythroid series derived from MYELOID PROGENITOR CELLS or from the bi-potential MEGAKARYOCYTE-ERYTHROID PROGENITOR CELLS which eventually give rise to mature RED BLOOD CELLS. The erythroid progenitor cells develop in two phases: erythroid burst-forming units (BFU-E) followed by erythroid colony-forming units (CFU-E); BFU-E differentiate into CFU-E on stimulation by ERYTHROPOIETIN, and then further differentiate into ERYTHROBLASTS when stimulated by other factors. | Red blood cell precursor|Erythroid Precursor Cell|Cell, Erythroid Precursor|Cells, Erythroid Precursor|red blood cell precursor|Precursor Cell, Erythroid|Precursor Cells, Erythroid|erythrocyte precursor|Red blood cell precursor (cell)|Erythroid precursor cell|Erythroid Precursor Cells | Erythroid Precursor Cells |
C0242912 | Drugs intended to prevent damage to the brain or spinal cord from ischemia, stroke, convulsions, or trauma. Some must be administered before the event, but others may be effective for some time after. They act by a variety of mechanisms, but often directly or indirectly minimize the damage produced by endogenous excitatory amino acids. | Agents, Neuroprotective|neuroprotectant|neuroprotective drug|Neuroprotective Agent|Neuroprotectants|Neuroprotective agents|Drugs, Neuroprotective|neuroprotective agents|Neuroprotective Drugs | Neuroprotective Agents |
C0518031 | The ability to sustain an activity over a period of time. | Stamina|Endurance|stamina|Stamina (finding)|Endurance capacity|endurance|Endurance (observable entity) | Endurance |
C0232478 | Taking into the body by mouth. | eat and drink by mouth|ingestions|Ingestion|ingested|ingestion|ingest|ingesting|Ingestion (observable entity)|Ingested | Ingestion |
C0086231 | Any of several immunoassay methods that use an enzyme covalently linked to an antigen or antibody as a label; the most common types are enzyme-linked immunosorbent assay (ELISA) and enzyme-multiplied immunoassay technique (EMIT). | Enzyme Immunoassays|enzyme immunoassays|Enzyme immunoassay, NOS|Immunoenzymatic assay, NOS|Enzyme Immunoassay|EIA|EIA method|EIA procedure, NOS|Immunoassays, Enzyme|Enzyme immunoassay method (procedure)|Enzyme immunoassay technique|Enzyme immunoassay method|enzyme immunoassay|Immunologic, Enzyme Linked Immunoassay|EIA technique|Enzyme immunoassay|Enzyme immunoassay technique (qualifier value)|Immunoassay, Enzyme | Enzyme Immunoassay |
C0038615 | A flavoprotein containing oxidoreductase that catalyzes the dehydrogenation of SUCCINATE to fumarate. In most eukaryotic organisms this enzyme is a component of mitochondrial electron transport complex II. | Fumarate reductase|Reductase, Fumarate|SDH|Fumarate Reductase|Succinate dehydrogenase (substance)|Fumaric hydrogenase|Succinic dehydrogenase|fumarate hydrogenase|Succinate Dehydrogenase|Succinate dehydrogenase|Succinic Dehydrogenase|Succinic Oxidase|Oxidase, Succinic|Dehydrogenase, Succinate|succinate dehydrogenase|Dehydrogenase, Succinic | Succinate Dehydrogenase |
C0030422 | A relatively rare, usually benign neoplasm originating in the chemoreceptor tissue of the CAROTID BODY; GLOMUS JUGULARE; GLOMUS TYMPANICUM; AORTIC BODIES; and the female genital tract. It consists histologically of rounded or ovoid hyperchromatic cells that tend to be grouped in an alveolus-like pattern within a scant to moderate amount of fibrous stroma and a few large thin-walled vascular channels. (From Stedman, 27th ed) | Paraganglioma, Extra Adrenal|CHEMODECTOMA|PARAGANGLIOMAS, FAMILIAL NONCHROMAFFIN, 1|Nonchromaffin paraganglioma, NOS|Paraganglioma, Nonchromaffin|Paragangliomas, Extra-Adrenal|PARAGANGLIOMA, NONCHROMAFFIN|Paragangliomas, Non-Chromaffin|Paraganglioma, Extra-Adrenal|Non-chromaffin paraganglioma|Non-Chromaffin Paraganglioma|Chemodectomas|Extra-Adrenal Paraganglioma|Nonchromaffin Paraganglioma|Extra-Adrenal Paragangliomas|Chemodectoma|Extra-adrenal paraganglioma, NOS|Extra-adrenal paraganglioma|Extraadrenal Paraganglioma|Paragangliomas, Familial Nonchromaffin, 1|Nonchromaffin Paragangliomas|chemodectoma|Paraganglioma, Non Chromaffin|Non-Chromaffin Paragangliomas|Extra-adrenal paraganglioma (morphologic abnormality)|Paraganglioma, Non-Chromaffin|Nonchromaffin paraganglioma|Extra-Adrenal Paraganglionic Neoplasm|Paragangliomas, Nonchromaffin|Chemodectoma syndrome|Extra-adrenal paraganglioma (disorder) | Extra-Adrenal Paraganglioma |
C0018854 | A clonal disorder characterized by the secretion of a truncated gamma chain. In most cases, it is associated with morphologic changes also seen in lymphoplasmacytic lymphomas, but the clinical course is typically more aggressive than in lymphoplasmacytic lymphoma. | GAMMA HEAVY-CHAIN DISEASE|franklin's disease|Heavy chain disease, IgG type|Franklin disease|franklin disease|Franklins Disease|gamma Chain Disease|Franklin's disease|Gamma heavy chain disease|franklins disease|Gamma heavy chain disease (disorder)|GAMMA CHAIN DISEASE|IgG heavy chain disease|Gamma heavy chain disease (clinical)|Franklin's Disease|FRANKLIN DISEASE|gamma heavy chain disease|Gamma heavy-chain disease|Franklin Disease|Gamma Heavy Chain Disease|GAMMA HCD|IGG HEAVY CHAIN DISEASE|gamma-Chain Diseases | gamma-Chain Disease |
C0432562 | A non-Hodgkin lymphoma or rarely Hodgkin lymphoma that arises from the spleen. | Malignant lymphoma of spleen (disorder)|lymphoma splenic|Malignant lymphoma, NOS of spleen|spleen lymphoma|Primary Splenic Lymphoma|lymphoma spleen|Splenic Lymphoma|splenic lymphoma | Malignant lymphoma of spleen |
C0443742 | null | Gamma heavy chain (substance) | Gamma heavy chain |
C0013492 | Simple sweat glands that secrete sweat directly onto the SKIN. | eccrine sweat gland|Eccrine Glands|Eccrine gland|Glands, Eccrine|eccrine gland|Eccrine gland structure (body structure)|Eccrine Sweat Gland|Eccrine gland, NOS|Eccrine sweat gland|Eccrine gland structure|Eccrine Gland|Gland, Eccrine|eccrine glands sweat|eccrine glands | Eccrine Glands |
C0013492 | Simple sweat glands that secrete sweat directly onto the SKIN. | eccrine sweat gland|Eccrine Glands|Eccrine gland|Glands, Eccrine|eccrine gland|Eccrine gland structure (body structure)|Eccrine Sweat Gland|Eccrine gland, NOS|Eccrine sweat gland|Eccrine gland structure|Eccrine Gland|Gland, Eccrine|eccrine glands sweat|eccrine glands | Eccrine Glands |
C0016875 | An antibiotic isolated from the fermentation broth of Fusidium coccineum. (From Merck Index, 11th ed). It acts by inhibiting translocation during protein synthesis. | Acid, Fusidic|Fusidic acid (substance)|Fusidic acid|29-Nordammara-17(20),24-dien-21-oic acid, 16-(acetyloxy)-3,11-dihydroxy-, (3alpha,4alpha,8alpha,9beta,11alpha,13alpha,14beta,16beta,17Z)-|Fusidine|fusidic acid eye|fusidic acid|Fusidic acid-containing product|ácido fusídico|Fucidin acid|acid fusidic|Product containing fusidic acid (medicinal product)|FUSIDIC ACID|Fusidic Acid | fusidic acid |
C0178587 | The amount of something per unit size. | physical density|density|Density|DEN|densities|DENSITY|density (physics)|Density (qualifier value)|Mass to volume ratio | density |
C0038433 | null | Streptozocin Diabete|Streptozocin Diabetes|Diabete, Streptozocin|Diabetes, Streptozocin|Diabetes, Streptozotocin | Streptozotocin Diabetes |
C1535939 | Pneumonia resulting from infection with Pneumocystis jirovecii, frequently seen in the immunologically compromised, such as persons with AIDS, or steroid-treated individuals, the elderly, or premature or debilitated babies during their first three months. Patients may be only slightly febrile (or even afebrile), but are likely to be extremely weak, dyspneic, and cyanotic. This is a major cause of morbidity among patients with AIDS. | Pneumocystis jirovecii Pneumonia|PJP|PCP Infection|Pneumocystis Carinii Pneumonia|Pneumonia due to Pneumocystis carinii|Pneumocystis jirovecii pneumonia|Pneumocystis carinii pneumonia|pneumocystis pneumonia|PNEUMONIA, PNEUMOCYSTIS|Pneumonia, Pneumocystis carinii|pcp|Pneumocystis pneumonia|Pneumocystis|Pneumonia, Interstitial Plasma Cell|Pneumocystis carinii Pneumonia|PNEUMONIA, PNEUMOCYSTIS CARINII|Pneumocystis Pneumonias|pneumocystis carinii pneumonia (PCP)|Pneumocystoses|PNEUMONIA, INTERSTITIAL PLASMA CELL|Pulmonary pneumocystosis|Pneumocystosis (disorder)|Pneumocystosis|PCP|Interstitial plasma cell pneumonia|pneumocystosis|PNEUMOCYSTIS CARINII PNEUMONIA|PCP - Pneumocystis pneumonia|PCP Infections|Pneumocystosis, pulmonary|Infection, PCP|Pneumocystis Pneumonia|Pneumonia, Pneumocystis jirovecii|interstitial plasma cell pneumonia|PNEUMOCYSTIS PNEUMONIA|Pneumocystosis jirovecii pneumonia|Pneumonia, Pneumocystis|Pneumocystosis jirovecii pneumonia (disorder)|Pneumocystosis pneumonia|pneumocystis carinii pneumonia | Pneumocystis jiroveci pneumonia |
C0225776 | The layer investing the lungs and dipping into the fissures between the several lobes. | Pleura, Visceral|visceral pleura|Visceral Pleura|Visceral pleura structure|Pleura visceralis|pleura visceral|Pulmonary pleura|Visceral pleura structure (body structure)|Pleura pulmonalis|Pleura visceralis (pulmonalis)|pleura pulmonary|Visceral pleura | Visceral pleura |
C1269886 | null | Entire left subclavian artery (body structure)|Entire left subclavian artery | Entire left subclavian artery |
C1451432 | null | LPS-02-10-L-D09 | LPS 02-10-L-D09 |
C1451432 | null | LPS-02-10-L-D09 | LPS 02-10-L-D09 |
C1281512 | null | Entire abortus|Entire abortus (body structure) | Entire abortus |
C1168178 | null | null | saphenectomy |
C0043292 | The female sex chromosome, being the differential sex chromosome carried by half the male gametes and all female gametes in human and other male-heterogametic species. | Chromosome, X|chromosomes female sex|x sex chromosome|chromosomes x|X Chromosomes|x chromosome|Chromosome X|chromosome x|Female sex chromosome|Sex chromosome X|X Chromosome|Sex chromosome X (cell structure)|Chromosomes, X|X chromosome|x chromosomes | X Chromosome |
C0021308 | Formation of an infarct, which is NECROSIS in tissue due to local ISCHEMIA resulting from obstruction of BLOOD CIRCULATION, most commonly by a THROMBUS or EMBOLUS. | Infarction|Infarcts|INFARCTS|Infarctions|infarct|INFARCT INFARCTION|INFARCT|Infarct, NOS|Infarction, NOS|infarction|Infarct (morphologic abnormality)|Infarct | Infarction |
C0206077 | A non-invasive technique using ultrasound for the measurement of cerebrovascular hemodynamics, particularly cerebral blood flow velocity and cerebral collateral flow. With a high-intensity, low-frequency pulse probe, the intracranial arteries may be studied transtemporally, transorbitally, or from below the foramen magnum. | transcranial doppler|Transcranial doppler ultrasonography (procedure)|transcranial doppler sonography|Sonography, Transcranial Doppler|Transcranial doppler ultrasonography|TCD|Doppler Transcranial Ultrasonography|Ultrasonography, Doppler Transcranial|Doppler Ultrasonography, Transcranial|Transcranial Sonography, Doppler|Doppler Sonography, Transcranial|Non-imaging TCD|Transcranial Doppler Sonography|Transcranial Doppler ultrasonography|Transcranial Ultrasonography, Doppler|Transcranial doppler ultrasonography (US)|Transcranial Doppler Ultrasound|Ultrasonography, Transcranial Doppler|Sonography, Doppler Transcranial|Ultrasonography, Doppler, Transcranial|Doppler Transcranial Sonography|Transcranial Doppler (TCD) Ultrasonography|Transcranial Doppler Ultrasonography | Ultrasonography, Doppler, Transcranial |
C0221018 | An inherited form of sideroblastic anemia. | Anemia, hereditary sideroblastic|ANEMIA, HEREDITARY SIDEROBLASTIC|Hereditary Sideroblastic Anemia|Hereditary sideroblastic anemia, NOS|Hereditary sideroblastic anaemia, NOS|Congenital sideroblastic anemia|Congenital sideroblastic anaemia|Sideroblastic anemia, hereditary|Anemia, congenital sideroblastic | Hereditary sideroblastic anemia |
C0596803 | sum of chemical changes that occur within the tissues of an organism consisting of anabolism (biosynthesis) and catabolism of iron; the buildup and breakdown of iron for utilization by the organism. | iron metabolism | iron metabolism |
C0599175 | The chemical reactions and pathways resulting in the formation of heme, any compound of iron complexed in a porphyrin (tetrapyrrole) ring, from less complex precursors. [GOC:jl] | heme anabolism|heme biosynthesis|haem biosynthetic process|heme formation|haem biosynthesis|heme synthesis | heme biosynthetic process |
C0272286 | A general class of thrombocytopenia due to immune destruction of platelets. It includes idiopathic thrombocytopenic purpura, as well as immune destruction-related thrombocytopenias due to other reasons (e.g., AIDS, transfusion, lupus erythematosus). | Immune thrombocytopenia|Thrombocytopenia (due to): platelet alloimmunization|Thrombocytopenia due to enhanced destruction, immune|immune thrombocytopenia|Immune Thrombocytopenia|Thrombocytopenia due to immune destruction|Thrombocytopenia due to immune destruction, NOS|Thrombocytopenia Due to Immune Destruction|Immune thrombocytopenia (disorder)|Thrombocytopenia due to platelet alloimmunization|Immune-mediated thrombocytopenia | Thrombocytopenia due to platelet alloimmunization |
C0032051 | Failure of the PLACENTA to deliver an adequate supply of nutrients and OXYGEN to the FETUS. | Placental insufficiency|Placental insufficiency syndrome|placental insufficiency|Placental insufficiency (disorder)|Chronic fetal deprivation syndrome|Insufficiency, Placental|insufficiency placental | Placental Insufficiency |
C0086818 | The transfer of blood platelets from a donor to a recipient or reinfusion to the donor. | blood platelets transfusion|Blood Platelet Transfusions|Transfusion of platelets|platelets transfusion|Platelet Transfusions|Transfusion of thrombocytes|Platelet Transfusion|Platelet Transfusion, Blood|Blood platelets--Transfusion|Transfusions, Blood Platelet|platelet transfusions|Intravenous blood transfusion of platelets|Platelet Transfusions, Blood|Transfusions, Platelet|Platelet transfusion (procedure)|platelet transfusion|transfusion platelets|platelets transfusions|Platelet transfusion|Blood Platelet Transfusion|Transfusion, Platelet|Transfusion, Blood Platelet|Intravenous blood transfusion of platelets (procedure) | Platelet Transfusion |
C0242584 | The presence of thrombocytopenia in combination with detection of antiplatelet antibodies. [DDD:wouwehand] | Autoimmune thrombocytopenia|autoimmune thrombocytopenia|Thrombocytopenia, autoimmune|Immune thrombocytopenia|Autoimmune thrombocytopenia (disorder) | Autoimmune thrombocytopenia |
C0004364 | Disorders that are characterized by the production of antibodies that react with host tissues or immune effector cells that are autoreactive to endogenous peptides. | Autoimmune disorder|Autoimmune disease NOS|autoimmunities|Autoimmune disease|autoimmune disorder|Disease, Autoimmune|autoimmunity|AUTOIMMUNE DISEASE|Autoimmune Disorders|Autoimmune Disease|Autoimmune condition|Autoimmune diseases|autoimmune diseases|Autoimmune disorder, NOS|autoimmune disease|autoimmune disorders|Autoimmune Diseases|Autoimmune disease (disorder)|self recognition (immune)|Autoimmune Disorder|AUTOIMMUNE DISORDER|Autoimmune disease, NOS|Diseases, Autoimmune|Autoimmune disorders | Autoimmune Diseases |
C0032181 | The number of PLATELETS per unit volume in a sample of venous BLOOD. | platelets count|Platelet Count, Blood|Platelet count|Platelet Numbers, Blood|Platelet Numbers|Platelet Counts|platelet count|Platelet count (procedure)|Blood Platelet Numbers|blood platelet counts|Plt - Platelet count|Number, Platelet|Platelet count - observation|Platelets|Counts, Blood Platelet|Count, Platelet|platelet number|Platelet Number|Numbers, Platelet|Counts, Platelet|thrombocyte count|Anucleated Thrombocytes|Number, Blood Platelet|Platelet Counts, Blood|Blood Platelet Count|Numbers, Blood Platelet|Blood Platelet Counts|Platelet Number, Blood|Platelet Count|Whole Blood Platelet Counts|Blood Platelet Number|Count, Blood Platelet|platelet counts|PLAT|blood platelet count|blood platelet numbers | Platelet Count measurement |
C0993624 | null | analyzer hematology | hematology analyzers |
C0520459 | ENTEROCOLITIS with extensive ulceration (ULCER) and NECROSIS. It is observed primarily in LOW BIRTH WEIGHT INFANT. | Enterocolitis, Necrotizing|ENTEROCOLITIS, NECROTIZING|Necrotizing Enterocolitis|ENTEROCOLITIS NECROTIZING | Necrotizing Enterocolitis |
C0032172 | A phospholipid derivative formed by PLATELETS; BASOPHILS; NEUTROPHILS; MONOCYTES; and MACROPHAGES. It is a potent platelet aggregating agent and inducer of systemic anaphylactic symptoms, including HYPOTENSION; THROMBOCYTOPENIA; NEUTROPENIA; and BRONCHOCONSTRICTION. | paf|Platelet-Activating Substance|platelet activating factor (PAF)|Platelet Activating Substance|Platelet Aggregating Factor|Thrombocyte Aggregating Activity|1 Alkyl 2 acetyl sn glycerophosphocholine|Aggregating Factor, Platelet|Phosphorylcholine, Acetyl Glyceryl Ether|AGEPC|Platelet activating factor (substance)|platelet-activating factor|1-O-alkyl-2-acetyl-sn-glycero-3-phosphocholine|PAF-Acether|platelet activating factor|Acetyl Glyceryl Ether Phosphorylcholine|Platelet Activating Factor|PAF|1-Alkyl-2-acetyl-sn-glycerophosphocholine|Platelet Aggregation Enhancing Factor|Factor, Platelet Activating|Platelet activating factor|PAF Acether | Platelet Activating Factor |
C0398650 | Thrombocytopenia occurring in the absence of toxic exposure or a disease associated with decreased platelets. It is mediated by immune mechanisms, in most cases IMMUNOGLOBULIN G autoantibodies which attach to platelets and subsequently undergo destruction by macrophages. The disease is seen in acute (affecting children) and chronic (adult) forms. | Werlhof Disease|Idiopathic purpura, NOS|Purpura, Thrombocytopenic, Autoimmune|thrombocytopenic purpura immune|Immune Thrombocytopenia|WERLHOF DISEASE|Purpuras, Idiopathic Thrombocytopenic|idiopathic thrombocytopenia purpura|itp|Idiopathic Thrombocytopenia Purpura|Autoimmune Thrombocytopenia|ITP|Purpuras, Autoimmune Thrombocytopenic|Thrombocytopenias, Autoimmune|Autoimmune Thrombocytopenias|Thrombocytopenic Purpura, Idiopathic|idiopathic purpura|PURPURA, THROMBOCYTOPENIC, IDIOPATHIC|werlhof's disease|ITP - immune thrombocytopenic purpura|AITP|Purpura, Immune Thrombocytopenic|Thrombocytopenic Purpura, Immune|idiopathic thrombocytopenic purpura (ITP)|idiopathic thrombocytopenic purpura|Thrombocytopenias, Immune|immune purpura thrombocytopenic|Purpura, Autoimmune Thrombocytopenic|Thrombocytopenic Purpuras, Immune|Idiopathic Thrombocytopenic Purpura|Autoimmune Thrombocytopenic Purpura|Autoimmune thrombocytopenic purpura|Thrombocytopenia, Autoimmune|Purpura, Thrombocytopenic, Idiopathic|immune thrombocytopenic purpura|Werlhof's disease|IMMUNE THROMBOCYTOPENIC PURPURA|Disease, Werlhof|Idiopathic thrombocytopenic purpura, NOS|Idiopathic thrombocytopenia purpura|Werlhofs Disease|Idiopathic thrombocytopenic purpura (disorder)|Immune Thrombocytopenic Purpura|Purpuras, Immune Thrombocytopenic|Idiopathic Thrombocytopenic Purpuras|Thrombocytopenic Purpura, Autoimmune|Immune Thrombocytopenias|ITP, NOS|Immune Thrombocytopenic Purpuras|Idiopathic purpura|Werlhof's Disease|Autoimmune Thrombocytopenic Purpuras|Purpura, Idiopathic Thrombocytopenic|Thrombocytopenic Purpuras, Idiopathic|ITP - idiopathic thrombocytopenic purpura|Idiopathic Thrombocytopenia|Disease, Werlhof's|Idiopathic thrombocytopenic purpura|Idiopathic thrombocytopenic purpura (ITP)|Thrombocytopenia, Immune|Immune thrombocytopenic purpura|THROMBOCYTOPENIC PURPURA, AUTOIMMUNE|IDIOPATHIC THROMBOCYTOPENIC PURPURA | Immune thrombocytopenic purpura |
C0048470 | A synthetic derivative of L-arginine with antithrombotic activity. Argatroban is a univalent and direct inhibitor of fibrin-bound thrombin. This agent reversibly binds to the thrombin active site thereby preventing the thrombin-dependent reactions, which include conversion of fibrinogen to fibrin; the activation of factors V, VIII and XI; the activation of protein C; and platelet aggregation. Argatroban is highly selective for thrombin and is able to inhibit the action of both free and clot-associated thrombin. As a result, stabilization of blood clots and coagulation is inhibited. | 2-Piperidinecarboxylic acid, 1-(5-((aminoiminomethyl)amino)-1-oxo-2-(((1,2,3,4-tetrahydro-3-methyl-8-quinolinyl)sulfonyl)amino)pentyl)-4-methyl-|1-[5-guanidino-2-[(3-methyl-1,2,3,4-tetrahydroquinolin-8-yl)sulfonylamino]pentanoyl]-4-methyl-piperidine-2-carboxylic acid|MMTQAP|Argatroban|Argatroban (substance)|MPQA|Argipidine|Product containing argatroban (medicinal product)|Argatroban-containing product|4-methyl-1-(N(2)-(3-methyl-1,2,3,4-tetrahydro-8-quinolinesulfonyl)-L-arginyl)-2-piperidinecarboxylic acid|argatroban|ARGATROBAN | argatroban |
C0272285 | A life-threatening complication of heparin therapy. It results in immune-mediated thrombocytopenia and, in 25-50 percent of the patients, thrombotic complications. | Heparin-induced thrombocytopenia|Heparin-induced thrombocytopenia (HIT)|Heparin induced thrombocytopaenia|Heparin induced thrombocytopenia|Heparin-induced thrombocytopenia (disorder)|Heparin Induced Thrombocytopenia|HIT|Heparin-Induced Thrombocytopenia|heparin-induced thrombocytopenia|heparin induced thrombocytopenia | Heparin-induced thrombocytopenia |
C0048470 | A synthetic derivative of L-arginine with antithrombotic activity. Argatroban is a univalent and direct inhibitor of fibrin-bound thrombin. This agent reversibly binds to the thrombin active site thereby preventing the thrombin-dependent reactions, which include conversion of fibrinogen to fibrin; the activation of factors V, VIII and XI; the activation of protein C; and platelet aggregation. Argatroban is highly selective for thrombin and is able to inhibit the action of both free and clot-associated thrombin. As a result, stabilization of blood clots and coagulation is inhibited. | 2-Piperidinecarboxylic acid, 1-(5-((aminoiminomethyl)amino)-1-oxo-2-(((1,2,3,4-tetrahydro-3-methyl-8-quinolinyl)sulfonyl)amino)pentyl)-4-methyl-|1-[5-guanidino-2-[(3-methyl-1,2,3,4-tetrahydroquinolin-8-yl)sulfonylamino]pentanoyl]-4-methyl-piperidine-2-carboxylic acid|MMTQAP|Argatroban|Argatroban (substance)|MPQA|Argipidine|Product containing argatroban (medicinal product)|Argatroban-containing product|4-methyl-1-(N(2)-(3-methyl-1,2,3,4-tetrahydro-8-quinolinesulfonyl)-L-arginyl)-2-piperidinecarboxylic acid|argatroban|ARGATROBAN | argatroban |
C0035920 | An acute infectious disease caused by the RUBELLA VIRUS. The virus enters the respiratory tract via airborne droplet and spreads to the LYMPHATIC SYSTEM. | Measle, Three Day|GERMAN MEASLES|Rubellas|Measles, German|German measles|Three Day Measle|rubella|Rubella|german measles|german measle|Three Day Measles|Measles, Three Day|third disease|RUBELLA|three-day measles|THIRD DISEASE|Rubella (disorder)|German Measles|german measles rubella|Three day measles|Rubella, NOS|Rubella without mention of complication|Rubella Infection | Rubella |
C0318356 | Viruses which routinely infect humans | human virus|Human Virus|Human virus, NOS|humans virus|Human virus (organism)|Viruses, Human|virus human | Human virus |
Subsets and Splits
No community queries yet
The top public SQL queries from the community will appear here once available.